KPV peptide (Lysine-Proline-Valine) delivers targeted anti-inflammatory activity without the immune suppression caused by conventional pharmaceutical treatments. Derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), KPV retains the full anti-inflammatory potency of its parent molecule while eliminating α-MSH’s pigmentation-altering effects.

KPV (Lysine-Proline-Valine) is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid neuropeptide produced by the pituitary gland and various immune cells. Despite being only three amino acids long, KPV peptide retains the full anti-inflammatory potency of the parent hormone — and in some assays, exceeds it — while lacking α-MSH’s pigmentation-altering effects.

What makes this tripeptide unique in the anti-inflammatory landscape is its selectivity: it suppresses excessive inflammation without broadly suppressing immune function. Most pharmaceutical anti-inflammatories (corticosteroids, NSAIDs, immunosuppressants) achieve their effects by dampening the immune system as a whole. KPV peptide targets specific inflammatory pathways while leaving immune defense mechanisms intact.

Chemical Profile

Sequence: Lysine-Proline-Valine (Lys-Pro-Val) | Molecular Weight: 342.43 Da | CAS: 67727-97-3 | Parent molecule: α-Melanocyte-Stimulating Hormone (α-MSH, positions 11-13) | Classification: Melanocortin-derived anti-inflammatory peptide

The KPV peptide sequence is extraordinarily compact — just three amino acids — yet it encodes functional activity that rivals the 13-amino acid parent hormone in several inflammatory assay systems. This size advantage translates to greater tissue penetration, improved oral bioavailability via peptide transporters, and reduced metabolic burden compared to larger peptide analogs studied in the same research contexts.

KPV Peptide Mechanisms of Action

NF-κB Pathway Suppression

The primary anti-inflammatory mechanism of KPV peptide is suppression of Nuclear Factor kappa-B (NF-κB) — one of the most important transcription factors in inflammatory biology. NF-κB acts as a master switch that controls the expression of dozens of pro-inflammatory genes. When activated, it drives production of TNF-α, IL-6, IL-1β, nitric oxide, and other inflammatory mediators.

Published research (2012, International Journal of Physiology, Pathophysiology and Pharmacology) demonstrated that KPV suppresses NF-κB activation, reducing downstream expression of inflammatory genes. This is mechanistically distinct from how BPC-157 (nitric oxide modulation) or GHK-Cu (cytokine reduction) address inflammation — making KPV a non-redundant addition in multi-peptide research protocols.

Pro-Inflammatory Cytokine Reduction

KPV significantly downregulates TNF-α — a major pro-inflammatory cytokine encoded by the TNFA gene that uses the NF-κB pathway. A 2017 mouse model study observed significant TNF-α downregulation following KPV peptide administration. The compound also reduces IL-6 and IL-1β secretion in activated immune cells and keratinocytes, providing broad cytokine-level inflammation control.

Antimicrobial Activity

Published research in the Journal of Leukocyte Biology (Cutuli et al., 2000) demonstrated that KPV significantly inhibits colony formation of Staphylococcus aureus and reduces viability and germ tube formation of Candida albicans — even at physiological (picomolar) concentrations.

Critically, the researchers found that KPV peptide did not reduce neutrophil killing capacity. Most anti-inflammatory drugs decrease the body’s ability to fight pathogens as a side effect of dampening immune function. KPV achieves anti-inflammatory effects while preserving — and actually enhancing — antimicrobial defense. The researchers concluded that this dual action could be useful in conditions where infection and inflammation coexist.

Skin Protection

A 2025 study published in ScienceDirect investigated the protective effects of KPV against PM10 (particulate matter) damage in human keratinocytes. Treatment restored cell viability, reduced IL-1β secretion, inhibited ROS (reactive oxygen species) production, and decreased apoptosis-related protein expression. In a 3D skin model, KPV peptide effectively attenuated inflammatory cell death induced by environmental pollutants. Researchers noted dose-dependent cytoprotective effects without observable cytotoxicity.

Gut Inflammation Research

KPV peptide has demonstrated significant anti-inflammatory effects in preclinical colitis models. A notable finding is that KPV can be delivered orally via the PepT1 intestinal transporter (Dalmasso et al., 2008, Gastroenterology) — unusual for a peptide, as most are degraded in the GI tract. This oral bioavailability makes KPV particularly relevant for gut inflammation research. Hyaluronic acid-functionalized nanoparticles loaded with KPV have been shown to accelerate mucosal healing and reduce TNF-α in inflamed colonic tissue.

No Melanogenesis

Unlike full-length α-MSH and melanocortin analogs like Melanotan II, KPV peptide does not activate MC1R melanocortin receptors responsible for melanin production. Its activity is limited to anti-inflammatory and immunomodulatory effects with no skin darkening side effects. This selectivity is one of the primary reasons researchers prefer KPV over full-length α-MSH for anti-inflammatory studies.

Published Research: KPV Peptide Key Studies

The following studies represent the most cited and methodologically significant findings in the peer-reviewed literature on KPV peptide activity across different research models.

Cutuli et al. (2000) — Antimicrobial Properties: Published in the Journal of Leukocyte Biology, this study established that KPV at picomolar concentrations inhibits Staphylococcus aureus colony formation by approximately 60% and reduces Candida albicans viability and germ tube formation. Importantly, neutrophil killing capacity was not impaired — distinguishing KPV peptide from conventional antibiotics and immunosuppressants. This study remains a foundational reference for the dual anti-inflammatory/antimicrobial characterization of KPV.

Dalmasso et al. (2008) — Gut Bioavailability: Published in Gastroenterology, this study demonstrated that KPV peptide is transported intact across intestinal epithelial cells via the PepT1 (SLC15A1) peptide transporter. Oral administration in a murine colitis model reduced colonic inflammation by 40–55% compared to untreated controls, with significant decreases in TNF-α, IL-6, and NF-κB activation markers. This study is pivotal because oral bioavailability is rare for therapeutic peptides, most of which are degraded by gastrointestinal proteases.

Brzoska et al. (2008) — α-MSH Peptide Review: Published in Annals of the Rheumatic Diseases (PubMed), this comprehensive review confirmed that KPV peptide retains the functional anti-inflammatory profile of full-length α-MSH while exhibiting a superior safety profile due to the absence of melanocortin receptor-mediated pigmentation effects. The authors proposed KPV as a candidate for future anti-inflammatory research in rheumatological conditions.

PM10 Skin Protection (2025): This recent study investigated KPV as a protective agent against particulate matter-induced inflammatory damage in human keratinocyte cultures and 3D skin models. KPV peptide reduced inflammatory cell death, restored cell viability, and suppressed ROS production in a dose-dependent manner, extending the research applications of this tripeptide into environmental dermatology.

KPV Peptide Safety Profile

Preclinical research on KPV peptide has consistently demonstrated a favorable safety profile across the concentrations and delivery routes examined in published studies.

No cytotoxicity at research concentrations: In cell culture studies examining KPV activity in keratinocytes and intestinal epithelial cells, the peptide did not reduce cell viability at concentrations sufficient to produce anti-inflammatory effects. This distinguishes it from corticosteroids and NSAIDs, which demonstrate concentration-dependent cytotoxicity.

No immunosuppression: Unlike broad-spectrum anti-inflammatories, KPV peptide does not impair neutrophil killing capacity or reduce immune system activity against bacterial pathogens. In the Cutuli et al. (2000) study, KPV preserved and enhanced antimicrobial defense while simultaneously reducing inflammatory signaling.

No melanogenic activity: Repeated studies confirm that KPV does not activate MC1R melanocortin receptors. This distinguishes it from Melanotan II and other α-MSH analogs that produce significant skin darkening as an off-target effect. For researchers studying inflammatory pathways independent of pigmentation, KPV peptide provides a cleaner research tool.

Metabolic stability: KPV’s resistance to GI proteolysis (as evidenced by oral bioavailability via PepT1) suggests relative metabolic stability compared to larger peptides. As with all research peptides, appropriate storage and handling protocols must be followed to maintain integrity. For comprehensive guidance, see our peptide storage guide.

All safety data on KPV peptide referenced here is from in vitro and preclinical animal model research. KPV is sold exclusively for laboratory research use. Human safety data does not exist in the peer-reviewed literature.

KPV Peptide Research Protocol

The following protocol information is derived from published laboratory research on KPV peptide and reflects standard practice for research settings.

Reconstitution: KPV is typically reconstituted using bacteriostatic water or sterile water for injection. The lyophilized peptide should be reconstituted by adding the appropriate volume of diluent and gently swirling — not vortexed — to avoid degradation. For detailed guidance, see our peptide reconstitution guide.

Storage: Lyophilized KPV peptide should be stored at -20°C for long-term stability, protected from light and moisture. Once reconstituted, the solution should be stored at 2–8°C and used within 28 days. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided by preparing single-use aliquots. Consult our guide on how to detect peptide degradation.

Research concentrations: Published studies have used concentrations ranging from picomolar (antimicrobial studies) to micromolar ranges (cell viability and cytokine studies). The Cutuli et al. (2000) study demonstrated biological activity at picomolar concentrations. Gut inflammation studies (Dalmasso et al., 2008) employed concentrations sufficient to achieve detectable anti-inflammatory effects via PepT1-mediated transport.

Delivery routes studied: KPV peptide has been studied via subcutaneous injection, oral administration (via PepT1 transporter), nanoparticle-encapsulated delivery (hyaluronic acid formulations for colonic delivery), and topical application in keratinocyte studies. The oral route is notably effective for gut inflammation research due to PepT1-mediated uptake. For injection methodology, see our guide on subcutaneous vs intramuscular peptide injection.

KPV Peptide in the KLOW Blend

KPV peptide is the component that distinguishes PSPeptides’ KLOW blend from the GLOW blend. GLOW contains BPC-157, GHK-Cu, and TB-500 — covering angiogenesis, collagen synthesis, and cell migration. KLOW adds KPV to provide NF-κB-mediated anti-inflammatory control and antimicrobial activity — pathways not covered by the other three components. For a detailed breakdown, see our GLOW vs KLOW comparison guide.

KPV Peptide Frequently Asked Questions

Does KPV peptide cause skin darkening?

No. KPV does not activate MC1R melanocortin receptors responsible for melanin production. Unlike Melanotan II or full-length α-MSH, KPV peptide activity is limited to anti-inflammatory and immunomodulatory effects. This makes it a preferred research tool for anti-inflammatory studies where melanocyte activation would confound results.

How is KPV peptide different from BPC-157 for inflammation?

KPV peptide and BPC-157 target different inflammatory pathways. KPV suppresses NF-κB — a master transcription factor controlling inflammatory gene expression. BPC-157 modulates the nitric oxide system. These are complementary, non-redundant mechanisms, which is why they are combined in the KLOW blend. For detailed comparison, see our BPC-157 research guide.

Can KPV peptide be taken orally?

Published research demonstrates that KPV peptide can be absorbed via the PepT1 intestinal transporter, giving it oral bioavailability — unusual for a research peptide. The Dalmasso et al. (2008) study in Gastroenterology confirmed PepT1-mediated uptake and significant anti-inflammatory effects following oral administration in murine colitis models. This makes KPV particularly relevant for gut inflammation research. For broader context, see our peptides for gut health guide.

What is the relationship between KPV peptide and alpha-MSH?

KPV peptide is a tripeptide fragment derived from positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). Research has shown that KPV retains the anti-inflammatory potency of the full 13-amino acid parent molecule in several assay systems. The key distinction is that KPV lacks the N-terminal acetylation and the full melanocortin receptor binding sequence of α-MSH, meaning it does not drive melanogenesis while preserving the NF-κB-suppressing and cytokine-reducing properties.

How does KPV peptide compare to conventional anti-inflammatory drugs?

The key mechanistic difference is selectivity. NSAIDs inhibit COX enzymes involved in prostaglandin synthesis. Corticosteroids broadly suppress immune signaling across multiple pathways. KPV peptide specifically targets the NF-κB transcription pathway — a more upstream and selective intervention. In published literature, KPV has demonstrated anti-inflammatory activity comparable to these agents in cell models while preserving antimicrobial immune function. These are preclinical research findings; human clinical data does not exist for KPV peptide.

KPV Peptide vs Other Anti-Inflammatory Research Compounds

Researchers studying inflammatory pathways often need to compare available compounds to select the most appropriate tool for their model. The following comparison situates KPV peptide relative to other commonly researched anti-inflammatory peptides and compounds.

KPV peptide vs BPC-157: BPC-157 is a 15-amino acid peptide derived from human gastric juice protein. Its primary anti-inflammatory mechanism involves nitric oxide pathway modulation, while KPV peptide acts via NF-κB suppression. These are mechanistically independent pathways. BPC-157 has been more extensively studied in tendon, ligament, and gut repair contexts, while KPV shows stronger evidence in cytokine suppression and oral bioavailability via PepT1. In preclinical models, the two compounds address different facets of the inflammatory cascade without competing mechanisms, which is why they appear together in the KLOW blend formulation.

KPV peptide vs GHK-Cu: GHK-Cu (copper peptide) is a tripeptide with distinct anti-inflammatory properties centered on modulation of TGF-β signaling, copper transport, and reactive oxygen species neutralization. Unlike KPV peptide, GHK-Cu has a stronger research record in collagen synthesis, wound healing, and hair follicle biology. For anti-inflammatory research specifically targeting NF-κB or cytokine networks, KPV is the more direct research tool. For skin regeneration and collagen-related research, GHK-Cu is more appropriate. Many researchers use both compounds in complementary protocols.

KPV peptide vs Thymosin Alpha-1 (Tα1): Thymosin Alpha-1 is a 28-amino acid peptide known primarily for immune modulation — specifically enhancing T-cell activity and innate immune response. Unlike KPV peptide, Tα1 is more immunostimulatory than anti-inflammatory. KPV’s profile is more specifically suited to research focused on reducing cytokine-driven inflammation rather than enhancing immune activation. In research models combining both immune support and inflammation control, the two compounds are complementary rather than interchangeable.

KPV peptide vs NSAIDs (in research contexts): NSAIDs inhibit COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation and pain signaling. This mechanism is downstream of NF-κB activation. KPV peptide acts upstream, suppressing the NF-κB transcription factor that triggers the inflammatory cascade — before prostaglandin synthesis is initiated. Additionally, NSAIDs reduce platelet aggregation and suppress the gastric lining as off-target effects; KPV does not share these mechanism-related side effects in cell model research. These distinctions make KPV peptide a useful research tool for studying upstream versus downstream anti-inflammatory interventions.

Summary: Key Research Findings on KPV Peptide

The body of published research on KPV peptide establishes several consistent and reproducible findings that make it a notable subject of anti-inflammatory peptide research. Below is a summary of the core evidence base for researchers evaluating KPV.

Mechanism: KPV suppresses Nuclear Factor kappa-B (NF-κB), a central transcription factor in inflammatory gene regulation. This mechanism is distinct from and complementary to other research compounds including BPC-157 (nitric oxide pathway), GHK-Cu (TGF-β and cytokine modulation), and NSAIDs (COX enzyme inhibition).

Oral bioavailability: Unlike most research peptides, KPV peptide can be absorbed intact via the PepT1 intestinal transporter. This property has been confirmed in published research and in murine colitis models, where oral KPV administration produced measurable colonic anti-inflammatory effects. This makes KPV a particularly useful tool for gut inflammation research.

Preserved immune function: Research consistently shows that KPV does not impair neutrophil killing capacity or reduce antimicrobial immune function — a significant distinction from conventional immunosuppressive anti-inflammatories. In the Cutuli et al. (2000) study, KPV actually enhanced antimicrobial defense against S. aureus and C. albicans at picomolar concentrations.

No melanogenic activity: Unlike its parent compound α-MSH, KPV peptide does not activate MC1R receptors or drive melanin production. This makes it suitable for anti-inflammatory research models where skin pigmentation changes would confound results or represent an unwanted variable.

Skin and systemic applications: Preclinical research supports KPV’s utility in models of colitis, particulate matter-induced keratinocyte damage, and conditions where NF-κB-driven inflammation is a primary driver. The peptide’s small molecular size (342.43 Da) contributes to favorable tissue penetration characteristics in research models. Researchers interested in broader peptide anti-inflammatory research may also consult our overview of peptides for immune support.

References

1. Brzoska T, et al. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2008;67(Suppl 3):iii49-iii55. PubMed
2. Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. PubMed
3. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166-178. PubMed

All products are intended for laboratory research use only. Not for human consumption.

PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping

All PSPeptides products are sold exclusively for research and laboratory use.